Sanofi announced positive results from the pivotal Phase 3 LIBERTY-AFRS-AIMS trial showing Dupixent significantly improved outcomes for adults and children aged 6 years and older with allergic fungal ...
Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, ...
ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...
GlobalData on MSN
Dupixent set for ninth US approval after Phase III AFRS success
Sanofi and Regeneron’s Dupixent (dupilumab) could be set for its ninth US approval after the drug met all the primary and secondary endpoints in a Phase III study in allergic fungal rhinosinusitis ...
Regeneron and Sanofi’s Dupixent trial shows major improvement in allergic fungal rhinosinusitis symptoms in patients 6+. Read ...
The condition, which most often affects people in warm, humid climates where fungal spores are common, can trigger nasal ...
Sanofi and Regeneron Pharmaceuticals said their jointly developed Dupixent anti-inflammatory blockbuster drug achieved primary and secondary goals in a late-stage study for allergic fungal ...
Sanofi & Regeneron’s Dupixent pivotal study meets all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis: Paris Monday, November 10, ...
Now, it’s worth noting Stock Advisor’s total average return is 1,062% — a market-crushing outperformance compared to 194 % ...
Results from the pivotal LIBERTY-AFRS-AIMS phase 3 study evaluating the investigational use of Dupixent in adults and ...
Most patients with chronic rhinosinusitis with nasal polyps no longer used oral corticosteroids after using dupilumab, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback